Results 271 to 280 of about 14,986,124 (359)

Last Study Treatment Time [PDF]

, 2020
openaire   +1 more source

Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study

, 2018
А В Кравченко, Elena Orlova‐Morozova, Tatiana Shimonova, О. А. Козырев, Ф. И. Нагимова, Nataliya Zaharova, Э. С. Иванова, У. А. Куимова, А. А. Попова, Oksana Chernova, O. S. Tonkih, Д. А. Гусев, A. A. Yakovlev, Vadim Pokrovsky, Вадим В. Бычко, Natalia Vostokova   +15 more
openalex   +2 more sources

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance

Haematologica, 2015
Ingrid M. Ariës, Rosanna E. van den Dungen, Marco J. Koudijs, Edwin Cuppen, Emile Voest, Jan J. Molenaar, Huib N. Caron, Rob Pieters, Monique L. den Boer   +8 more
doaj   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Polygenic Risk Scores for Glaucoma Onset in the Ocular Hypertension Treatment Study.

JAMA Ophthalmol
Singh RK, Zhao Y, Elze T, Fingert J, Gordon M, Kass MA, Luo Y, Pasquale LR, Scheetz T, Segrè AV, Wiggs JL, Zebardast N.   +11 more
europepmc   +1 more source

Medical comorbidities in bipolar disorder (BIPCOM): clinical validation of risk factors and biomarkers to improve prevention and treatment. Study protocol. [PDF]

Int J Bipolar Disord
de Girolamo G, Andreassen OA, Bauer M, Brambilla P, Calza S, Citerà N, Corcoy R, Fagiolini A, Garcia-Argibay M, Godin O, Klingler F, Kobayashi NF, Larsson H, Leboyer M, Matura S, Martinelli A, De la Peña-Arteaga V, Poli R, Reif A, Ritter P, Rødevand LN, Magno M, Caselani E, BIPCOM consortium.   +23 more
europepmc   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Machine Learning-Derived Baseline Visual Field Patterns Predict Future Glaucoma Onset in the Ocular Hypertension Treatment Study. [PDF]

Invest Ophthalmol Vis Sci
Singh RK, Smith S, Fingert J, Gordon M, Kass M, Scheetz T, Segrè AV, Wiggs J, Elze T, Zebardast N.   +9 more
europepmc   +1 more source

First Study Treatment Date [PDF]

, 2020
openaire   +1 more source